A recent study evaluated the feasibility and effectiveness of a multicomponent quality improvement strategy, known as C-QIP, aimed at enhancing chronic cardiovascular disease (CVD) care in India. Conducted among 410 adults with ischemic heart disease, ischemic stroke, or heart failure across four hospitals, the trial compared the C-QIP approach—which included electronic decision support, care coordination, patient education, and reminders—to usual care. Results indicated high retention rates, with 93.2% of C-QIP participants completing the study, and significant improvements in guideline-directed medical therapy (GDMT) for ischemic heart disease and stroke. Notably, adherence to medications, diet, and physical activity also improved among participants receiving the C-QIP intervention.
The findings underscore the potential of structured quality improvement strategies to address the fragmented care often experienced by patients with chronic CVD in India. With a median follow-up of 15 months, the study demonstrated that the C-QIP strategy was not only feasible but also acceptable to both patients and healthcare providers. However, the study's limitations include its design and the inability to draw definitive conclusions about long-term clinical outcomes such as heart attacks or mortality.
The authors advocate for larger, confirmatory trials to further explore the impact of such interventions on cardiovascular morbidity and mortality. This research is particularly relevant as it highlights the need for practical solutions to improve chronic disease management in resource-limited settings, where optimal care delivery remains a challenge.
PLOS Medicine · Sep 29A recent population cohort study involving 167,447 children born in Wales from 2009 to 2016 has revealed significant associations between prenatal exposure to maternal depression and antidepressant use, and the development of special educational needs (SEN) in children. The study, published in PLoS Medicine, aimed to clarify the long-term neurodevelopmental outcomes of children whose mothers experienced depression during pregnancy or were prescribed antidepressants. The findings indicate that 7.6% of children were exposed to untreated maternal depression, while 4.2% were exposed to treated depression, and 3.6% to antidepressants without a recorded depression diagnosis.
The results showed that children exposed to both maternal depression and antidepressants had the highest predicted probability of developing SEN, at 26.5 per 100 children, compared to 20.0 per 100 in unexposed children. Maternal depression alone was linked to a probability of 23.6 per 100, while antidepressant exposure without depression was associated with 26.3 per 100. Notably, antidepressant exposure was linked to a 6.3% absolute increase in SEN risk among children of mothers without depression, and a 2.9% increase among those with depression.
The study also highlighted specific neurodevelopmental disorders, finding significant associations with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The adjusted odds ratios indicated that antidepressant exposure was associated with an increased risk of ASD (aOR 1.59) and ADHD (aHR 1.89). However, the authors caution that the observed associations may be influenced by confounding factors such as the severity of maternal depression, suggesting that further research is necessary to disentangle these effects.
This study underscores the importance of understanding the implications of maternal mental health and medication use during pregnancy, as it may inform clinical decisions and patient counseling regarding antidepressant use in expectant mothers. As antidepressant prescriptions continue to rise, the need for comprehensive research into their long-term effects on child development remains critical.
PLOS Medicine · Sep 29A recent study has revealed that selective serotonin reuptake inhibitors (SSRIs) may enhance survival rates in cancer patients receiving immune checkpoint inhibitors (ICIs). Conducted using data from the TriNetX electronic health record network, the research compared outcomes between patients prescribed SSRIs and those on benzodiazepines (BZDs) while undergoing ICI treatment. The study included 1,567 matched pairs of patients with solid tumors and psychiatric comorbidities, revealing that 23.5% of the SSRI group died within two years compared to 34.4% in the BZD group, indicating a significant reduction in mortality associated with SSRI use (HR 0.627; p < 0.001).
In addition to improved survival, the SSRI group experienced a higher incidence of immune-related adverse events (irAEs), particularly thyroid dysfunction, but did not show increased rates of other serious complications such as hepatitis or pneumonitis. Notably, the study also found that patients on SSRIs had fewer newly coded distant metastases (HR 0.629; p < 0.001). These findings suggest that SSRIs may not only improve survival but also influence tumor immune microenvironments, as indicated by transcriptomic analyses from The Cancer Genome Atlas (TCGA), which showed an inverse correlation between serotonin transporter gene expression and T-cell infiltration in various cancer types.
The implications of this study are significant, as depression and anxiety affect a substantial proportion of cancer patients undergoing immunotherapy. The results support the potential repurposing of SSRIs as adjunctive therapy in this context, warranting further prospective trials to validate these findings and explore the underlying mechanisms. Given the limitations of the study, including potential confounding factors and the nature of the data, randomized controlled trials are essential to establish a causal relationship between SSRI use and improved outcomes in cancer immunotherapy.
PLOS Medicine · Sep 29